Exclusive: Charlton interested in loan deal for Crystal Palace attacker Rak-Sakyi
Charlton Athletic owner Thomas Sandgaard has confirmed negotiations are ongoing to sign Crystal Palace attacker Jesurun Rak-Sakyi on loan.
Tauroursodeoxycholic Acid Inhibits Clostridioides difficile Toxin-Induced Apoptosis
A roadmap for designing narrow-spectrum antibiotics targeting bacterial pathogens
Clostridioides difficile (Cdiff) infection (CDI) continues to be the leading threat of nosocomial deaths worldwide and a major burden on health-care systems. Broad-spectrum antibiotics eradicate the normal gut microbiome, killing protective commensal bacteria and increasing CDI recurre …
Tauroursodeoxycholic Acid Inhibits Clostridioides difficile Toxin-Induced Apoptosis
C. difficile infection (CDI) is a highly inflammatory disease mediated by the production of two large toxins that weaken the intestinal epithelium and cause extensive colonic tissue damage. Antibiotic alternative therapies for CDI are urgently needed as current antibiotic regimens prolong the pertur …
Functional and Metagenomic Evaluation of Ibezapolstat for Early Evaluation of Anti-Recurrence Effects in Clostridioides difficile Infection
Reduction of Clostridioides difficile infection (CDI) recurrence is an essential endpoint for CDI-directed antibiotic development that is often not evaluated until Phase III trials. The purpose of this project was to use a functional and metagenomic approach to predict the potential anti-CDI recurre …
Next-Generation Probiotic Therapy to Protect the Intestines From Injury
Probiotics are live microorganisms that, when administered in adequate amounts, provide health benefits to the host. Some strains of the probiotic Lactobacillus reuteri (L. reuteri) have both antimicrobial and anti-inflammatory properties that may be exploited for the treatment and pre …
Summit Therapeutics Provides Update on Ridinilazole
Menlo Park, CA, July 14, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” "we," or the “Company”) today provided an update...
Summit will take scenic route fda mountain after c diff convo regulator
Spore-forming probiotic blend shows potential for managing functional dyspepsia in adults
Long-term treatment of functional dyspepsia with proton-pump inhibitors can alter the gut microbiome. A new pilot randomized, double-blind, placebo-controlled trial suggests the potential of spore-forming probiotics in patients with functional dyspepsia.
Seres Therapeutics, armed with new safety data, eyes first FDA approval for a microbiome drug | Fierce Biotech
Micrococcin P2 Targets Clostridioides difficile
Clostridioides difficile infection is a global public health threat. Extensive in vitro assays using clinical isolates have identified micrococcin P2 (MP2, 1) as a particularly effective anti-C. difficile agent. MP2 possesses a mode of action that differs from other antib …
iNtRON Confirms Efficacy of CDL200 Against CDI Clinical Isolates - The Korea Herald
Shows potent and rapid antibacterial activity against clinical isolates in Europe and Korea both CDL200, a novel endolysin pipeline for the treatment of Clostridioides difficile Infection (CDI) The world's first endolysin in capsule formulation to be administered orally BOSTON and SEOUL, South Korea, July 12, 2022 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com) announc...
Seres Therapeutics Stock: The Good And The Challenging (NASDAQ:MCRB) - Seeking Alpha
While there's risk, Seres Therapeutics (MCRB) is well positioned for share price gain based on several factors. Click here to know those factors.
Immuron : Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease - Form 6-K - Marketscreener.com
Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease Melbourne, Australia, July 07, 2022: Immuron... | July 7, 2022
The five most advanced microbiome players aiming for the gut
After decades of research, gut microbiome therapies are on the cusp of reaching the market. Here are five of the companies that are closest to hitting this historic milestone.
Plotting a comeback after 2016 flop, Seres to raise $100M to prep C. difficile program for launch
Microbiome pioneer Seres Therapeutics faced numerous setbacks throughout the years in numerous fields, most prominently for its lead program in C. difficile infections. But the biotech has plotted a comeback after a major flop six years ago, and is confident enough to start seeking cash ahead of a possible market
Novel C. Difficile Treatment Reduces Recurrence in Key Subgroups
Paul Feuerstadt, MD, FACG, AGAF, discussed research into the novel C. difficile treatment RBX2660 and what investigators have found about its efficacy in key subgroup analyses.
RBX2660 for Recurrent CDI Associated with Microbiome and Bile Acid Restoration
Patients with recurrent Clostridioides difficile infection saw improvements in fecal microbiome and bile acid after treatment with the investigational microbiota-based live biotherapeutic RBX2660.
Immunoinformatics Approach Toward the Introduction of a Novel Multi-Epitope Vaccine Against Clostridium difficile
Clostridium difficile (C.difficile) is an exclusively anaerobic, spore-forming, and Gram-positive pathogen that is the most common cause of nosocomial diarrhea and is becoming increasingly prevalent in the community. Because C. difficile is strictly anaerobic, spores that can survive f …
New Therapeutic Repopulates the Gut Microbiome to Prevent Recurrent C Diff Infection - Contagionlive.com
Eric Shaff, president and CEO of Seres Therapeutics, discusses the confirmatory trial findings for SER-109. Seres is filing a Biologics License Application for the recurrent C diff therapy.
A Novel Therapeutic Repopulates the Gut Microbiome to Prevent Recurrent C Diff Infection
Eric Schaff, president and CEO of Seres Therapeutics, discusses the confirmatory trial findings for SER-109. Seres is filing a Biologics License Application for the recurrent C diff therapy.
In vitro anti-clostridial action and potential of the spice herbs essential oils to prevent biofilm formation of hypervirulent Clostridioides difficile strains isolated from hospitalized patients with CDI
Essential oils of wild oregano, black pepper and garlic are candidates for adjunctive therapeutics in the treatment of CDI. Oregano oil should certainly be preferred due to the lack of selectivity of action in relation to the ribotype, the strength of the produced biofilm and/or antibiotic-susceptib …
SER-109 Reduces Volume of Recurrent C Difficile Infection in Immunocompromised Patients
Patients with recurrent C difficile infection receiving SER-109 experienced reduced rates of infection as early as 4 weeks following treatment.
A Novel Therapeutic Repopulates the Gut Microbiome to Prevent Recurrent C Diff Infection
Eric Schaff, president and CEO of Seres Therapeutics, discusses the confirmatory trial findings for SER-109. Seres is filing a Biologics License Application for the recurrent C diff therapy.
RBX2660 Shows Consistent Safety, Efficacy for C. Diff
Paul Feuerstadt, MD, on the pooled analysis that compared medical history and demographics
.@PhaseGenomics received funding from the @GatesFoundation and @NIAIDFunding to develop an atlas of #phage-bacteria interactions and identify phages that can be used in therapeutic settings such as #Cdiff, #UlcerativeColitis, and #CrohnsDisease.
.@PhaseGenomics received funding from the @GatesFoundation and @NIAIDFunding to develop an atlas of #phage-bacteria interactions and identify phages that can be used in therapeutic settings such as #Cdiff, #UlcerativeColitis, and #CrohnsDisease.📍 https://t.co/NZmoL9Ltdo pic.twitter.com/kWpXRwokqw— Science in Seattle (@science_seattle) June 13, 2022
Saving Kids From Dangerous Infections With An Amoeba – Eurasia Review
Innovative efforts at the University of Virginia School of Medicine to use a harmless amoeba to protect children from dangerous infections has won critical financial support from The Hartwell …
Investigational Microbiome Therapeutic SER-109 Reduces C Difficile Recurrence
SER-109, the investigational oral microbiome therapeutic from Seres, reduced C diff recurrence by 91.3% in at-risk populations.
Clostridium Difficile Infection (CDI) Market Trends Analysis, Growth Opportunities and Challenges, Clinical Activities, Leading Companies, Emerging Therapies, and Epidemiology Forecast
DelveInsight’s “Clostridium Difficile Infection (CDI) Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Clostridium Difficile Infection (CDI), historical and forecasted epidemiology as well as the Clostridium Difficile Infection (CDI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. DelveInsight has launched a new […]
Identification of ADS024, a newly characterized strain of Bacillus velezensis with direct Clostridiodes difficile killing and toxin degradation bio-activities
Clostridioides difficile infection (CDI) remains a significant health threat worldwide. C. difficile is an opportunistic, toxigenic pathogen that takes advantage of a disrupted gut microbiome to grow and produce signs and symptoms ranging from diarrhea to pseudomembranous colitis. Antibiotics used t …